The ethics of pharmaceutical research funding: A social organization approach

Journal of Law, Medicine and Ethics

Volumn 41, Issue 3, 2013, Pages 629-634

  Gray, Garry C ^a  

^a HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DRUG INDUSTRY; ETHICS; FINANCIAL MANAGEMENT; HUMAN; MEDICAL ETHICS; PROFESSIONAL PRACTICE; RESEARCH ETHICS; SCIENTIFIC MISCONDUCT;

DRUG INDUSTRY; ETHICS, PROFESSIONAL; ETHICS, RESEARCH; HUMANS; PROFESSIONAL AUTONOMY; RESEARCH SUPPORT AS TOPIC; SCIENTIFIC MISCONDUCT;

EID: 84885106426     PISSN: 10731105     EISSN: 1748720X     Source Type: Journal    
DOI: 10.1111/jlme.12072     Document Type: Article

References (26)

1. G. Gray, "Insider Accounts of Institutional Corruption: Examining the Social Organization of Unethical Behaviour, " British Journal of Criminology 53, no. 4 (2013): 533-551
2. G. Gray and S. Silbey, quot;The Other Side of the Compliance Relationship," in C. Parker and V. Nielson, eds., Explaining Compliance: Understanding and Explaining Organizational Responses to Regulation (Cheltenham: Edward Elgar Publishing, 2011); N. Turner and G. Gray, quot;Socially Constructing Safety,"Human Relations 62, no. 9 (2009): 1259-1266
3. P. Ewick and S. Silbey, The Common Place of Law: Stories from Everyday Life (Chicago: University of Chicago Press, 1998); H. Garfinkel, quot;Studies of the Routine Grounds of Everyday Activities,"Social Problems 11, no. 3 (1964): 225-250
4. E. Sutherland, quot;White-Collar Criminality,"American Sociological Review 5, no. 1 (1940): 1-12.
5. D. Ariely, The (Honest) Truth about Dishonesty: How We Lie to Everyone, Especially Ourselves (New York : Harper Collins, 2012): at 67; Y. Feldman, R. Gauthier, and T. Schuller, "Curbing Misconduct in the Pharmaceutical Industry: Insights from Behavioral Ethics and the Behavioral Approach to Law, "Journal of Law, Medicine & Ethics 41, no. 3 (2013): 620-628; D. Cremer, D. Mayer, and M. Schminke, "On Understanding Ethical Behavior and Decision Making: A Behavioral Ethics Approach, "Business Ethics Quarterly 20, no. 1 (2010): 1-6.
6. Y. Feldman, R. Gauthier, and T. Schuller, quot;Curbing Misconduct in the Pharmaceutical Industry: Insights from Behavioral Ethics and the Behavioral Approach to Law,"Journal of Law, Medicine & Ethics 41, no. 3 (2013): 620-628
7. D. Cremer, D. Mayer, and M. Schminke, quot;On Understanding Ethical Behavior and Decision Making: A Behavioral Ethics Approach,"Business Ethics Quarterly 20, no. 1 (2010): 1-6.
8. M. Bazerman and F. Gino, "Behavioral Ethics: Toward a Deeper Understanding of Moral Judement and Dishonesty, " Annual Review of Law and Social Science 8 (2012): 85-104.
9. Professor Smith is a pseudonym. His account is part of a larger project carried being carried out by the author on the social organization of behavioral ethics across universities and institutions of public trust.
10. N. Olivieri, "Patients' Health or Company Profits? The Commercialization of Academic Research, " Science and Engineering Ethics 9, no. 1 (2003): 29-41.
11. A. Viens and J. Savulescu, "Introduction to the Oliveria Symposium, " Journal of Medical Ethics 30, no. 1 (2004): 1-7, at 2.
12. In this context the word "normal" refers to behaviors that become accepted practice among people in a particular group. I am not using it in the everyday sense of "ordinary."
13. G. Gray and V. Bishop-Kendzia, "Organizational Self-Censorship: Corporate Sponsorship, Nonprofit Funding, and the Educational Experience, " Canadian Review of Sociology 46, no. 2 (2009): 161-177.
14. L. Lessig, "Two Conceptions of 'Corruption, '" in Republic Lost: How Money Corrupts Congress - and a Plan to Stop It (New York : Twelve-Hackette Book Group, 2011): at 226-247
15. L. Lessig, "Foreword: 'Institutional Corruption' Defined, "Journal of Law, Medicine & Ethics 41, no. 3 (2013): 533-555.
16. M. Rodwin, "Conflicts of Interest, Institutional Corruption, and Pharma: An Agenda for Reform, "Journal of Law, Medicine & Ethics 40, no. 3 (2012): 511-522
17. M. Rodwin, "Rooting Out Institutional Corruption to Manage Inappropriate Off-Label Drug Use, "Journal of Law, Medicine & Ethics 41, no. 3 (2013): 654-664
18. P. D. Jorgensen, "Pharmaceuticals, Political Money, and Public Policy: A Theoretical and Empirical Agenda, "Journal of Law, Medicine & Ethics 41, no. 3 (2013): 561-570
19. S. Sismondo, "Key Opinion Leaders and the Corruption of Medical Knowledge: What the Sunshine Act Will and Won't Cast Light On, "Journal of Law, Medicine & Ethics, 41, no. 3 (2013): 635-643
20. S. Sah and A. Fugh-Berman, "Physicians under the Influence: Social Psychology and Industry Marketing Strategies, "Journal of Law, Medicine & Ethics 41, no. 3 (2013): 665-672
21. A. Brown, "Understanding Pharmaceutical Research Manipulation in the Context of Accounting Manipulation, "Journal of Law, Medicine & Ethics, 41, no. 3 (2013): 611-619
22. L. Cosgrove and E. E. Wheeler, "Drug Firms, the Codification of Diagnostic Categories, and Bias in Clinical Guidelines, "Journal of Law, Medicine, & Ethics 41, no. 3 (2013): 644-653
23. S. Rose, "Patient Advocacy Organizations: Institutional Conflicts of Interest, Trust, and Trustworthiness, "Journal of Law, Medicine, & Ethics 41, no. 3 (2013): 680-687
24. M.-A. Gagnon, "Corruption of Pharmaceutical Markets: Addressing the Misalignment between Financial Incentives and Public Health, "Journal of Law, Medicine & Ethics 41, no. 3 (2013): 571-580.
25. K. Austad, J. Avorn, J. Franklin, M. Kowal, E. Campbell, and A. Kesselheim, "Changing Interactions between Physician Trainees and the Pharmaceutical Industry: A National Survey, " Journal of General Internal Medicine 28, no. 8 (2013): 1064-1071.
26. R. K. Merton, "The Normative Structure of Science, " in R. K. Merton, ed., The Sociology of Science: Theoretical and Empirical Investigations (Chicago: University of Chicago Press, 1973).